Supernus Pharmaceuticals SUPN Number of reportable segments

Number of reportable segments at other companies

Jazz PharmaceuticalsJAZZ

0.3—

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Market cap$2.62B+62.8%

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NumberOfReportableSegments.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Supernus Pharmaceuticals's number of reportable segments?: Supernus Pharmaceuticals (SUPN) reported number of reportable segments of 1 in Q1 2026.